NASDAQ:CBAY

CymaBay Therapeutics - CBAY Stock Forecast, Price & News

$3.50

-0.07 (-1.96%)

(As of 09/29/2022 12:00 AM ET)

Add

Compare

Today's Range: $3.44
▼
$3.62
50-Day Range: $3.13
▼
$4.25
52-Week Range: $1.67
▼
$4.74

Volume: 284,181 shs
Average Volume: 395,363 shs
Market Capitalization: $296.38 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.00

CymaBay Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.33 Rating Score
Upside/Downside: 214.3% Upside
$11.00 Price Target
Short Interest: Healthy
2.23% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.88
Upright™ Environmental Score
News Sentiment: 1.71
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.21) to ($1.26) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.55 out of 5 stars

Medical Sector

167th out of 1,097 stocks

Pharmaceutical Preparations Industry

63rd out of 548 stocks

3.7

Analyst's Opinion

Consensus Rating
CymaBay Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $11.00, CymaBay Therapeutics has a forecasted upside of 214.3% from its current price of $3.50.
Amount of Analyst Coverage
CymaBay Therapeutics has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
2.23% of the float of CymaBay Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
CymaBay Therapeutics has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in CymaBay Therapeutics has recently decreased by 27.07%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
CymaBay Therapeutics does not currently pay a dividend.
Dividend Growth
CymaBay Therapeutics does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
CymaBay Therapeutics has received a 74.24% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for CymaBay Therapeutics is -0.88.

3.2

News and Social Media Coverage

News Sentiment
CymaBay Therapeutics has a news sentiment score of 1.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for CymaBay Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 11 people have searched for CBAY on MarketBeat in the last 30 days. This is a decrease of -61% compared to the previous 30 days.
MarketBeat Follows
Only 5 people have added CymaBay Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -38% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, CymaBay Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.60% of the stock of CymaBay Therapeutics is held by insiders.
Percentage Held by Institutions
74.92% of the stock of CymaBay Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for CymaBay Therapeutics are expected to decrease in the coming year, from ($1.21) to ($1.26) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of CymaBay Therapeutics is -2.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of CymaBay Therapeutics is -2.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
CymaBay Therapeutics has a P/B Ratio of 1.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About CymaBay Therapeutics (NASDAQ:CBAY) Stock

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

Receive CBAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CymaBay Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CBAY Stock News Headlines

September 14, 2022 | baystreet.ca

CymaBay to Host Virtual Analyst Day Next Week

September 14, 2022 | finance.yahoo.com

CymaBay Therapeutics Hosting Virtual Analyst Day on September 22

September 30, 2022 | Investing Trends (Ad)

The $193 Billion US-China War You Don't Know About

They're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.

August 30, 2022 | finance.yahoo.com

CymaBay Therapeutics (NASDAQ:CBAY) Has Debt But No Earnings; Should You Worry?

August 24, 2022 | finance.yahoo.com

CymaBay Therapeutics to Participate in B. Riley’s Mini PBC Symposium on August 24, 2022

August 16, 2022 | finance.yahoo.com

CymaBay Therapeutics Inc. (CBAY) Just Flashed Golden Cross Signal: Do You Buy?

August 13, 2022 | uk.investing.com

CymaBay Therapeutics Misses Q2 EPS by 2c

August 12, 2022 | finance.yahoo.com

CymaBay Therapeutics Inc. (CBAY) Q2 2022 Earnings Call Transcript

September 30, 2022 | Investing Trends (Ad)

Did Biden Bet the Future of America on the "Lithium Triangle"?

FREE investor's report details the plan to cut more ties with China and how it could create the next boom for early investors. But you must act fast.

August 11, 2022 | seekingalpha.com

Cymabay Therapeutics, Inc. (CBAY) CEO Sujal Shah on Q2 2022 Results - Earnings Call Transcript

August 11, 2022 | finance.yahoo.com

CymaBay Reports Second Quarter and Six Months Ended June 30, 2022 Financial Results and Provides Corporate Update

August 4, 2022 | finance.yahoo.com

CymaBay Therapeutics to Report Second Quarter of 2022 Financial Results on Thursday, August 11, 2022

August 2, 2022 | finance.yahoo.com

2 “Strong Buy” Penny Stocks With Substantial Upside Potential

August 1, 2022 | finance.yahoo.com

CymaBay Completes Enrollment for the RESPONSE Global Phase 3 Study Evaluating Seladelpar for Patients with Primary Biliary Cholangitis

July 22, 2022 | nasdaq.com

Multiple insiders bought CymaBay Therapeutics, Inc. (NASDAQ:CBAY) stock earlier this year, a positive sign for shareholders

June 27, 2022 | seekingalpha.com

CymaBay: Long-Term Potential Based On Prior PBC Trial Results

June 22, 2022 | marketwatch.com

CymaBay Therapeutics Shares Rise 7% After Positive Data for Seladelpar Trial

June 22, 2022 | finance.yahoo.com

CymaBay Therapeutics Presents Positive PBC Data at the International Liver Congress™ 2022

June 9, 2022 | finance.yahoo.com

Trade Alert: The President Of CymaBay Therapeutics, Inc. (NASDAQ:CBAY), Sujal Shah, Has Just Spent US$100k Buying 43% More Shares

June 8, 2022 | finance.yahoo.com

CymaBay Therapeutics Announces Presentations During The International Liver Congress™ 2022

May 23, 2022 | seekingalpha.com

CymaBay announces result from two-year study of primary biliary cholangitis therapy

May 23, 2022 | finance.yahoo.com

CymaBay's New Seladelpar Two-Year Data Shows Improved Transplant-Free Survival

May 23, 2022 | finance.yahoo.com

CymaBay Therapeutics Presents New Findings that Seladelpar Treatment of PBC Patients for Two Years Predicts Improved Transplant-Free Survival

May 16, 2022 | seekingalpha.com

CymaBay price target lowered at H.C. Wainwright on enrollment delay for key study

May 13, 2022 | benzinga.com

CymaBay Therapeutics: Q1 Earnings Insights

May 13, 2022 | seekingalpha.com

CymaBay Therapeutics GAAP EPS of -$0.32 misses by $0.01

May 13, 2022 | seekingalpha.com

CymaBay Therapeutics, Inc. (CBAY) CEO Sujal Shah on Q1 2022 Results - Earnings Call Transcript

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive CBAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CymaBay Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CBAY Company Calendar

Last Earnings: 8/11/2022
Today: 9/30/2022
Next Earnings (Estimated): 11/09/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CBAY
CUSIP: N/A
CIK: 1042074
Web: www.cymabay.com
Phone: (510) 293-8800
Fax: 510-293-9090
Employees: 59
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $11.00
High Stock Price Forecast: $14.00
Low Stock Price Forecast: $8.00
Forecasted Upside/Downside: +214.3%
Consensus Rating: Buy
Rating Score (0-4): 3.33
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.30)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-90,000,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -101.59%
Return on Assets: -59.18%

Debt

Debt-to-Equity Ratio: 1.00
Current Ratio: 13.27
Quick Ratio: 13.27

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.93 per share
Price / Book: 1.81

Miscellaneous

Outstanding Shares: 84,680,000
Free Float: 79,936,000
Market Cap: $296.38 million
Optionable: Optionable
Beta: 0.62

Key Executives

Mr. Sujal A. Shah (Age 49)
Pres, CEO & Director
Comp: $873.87k

Dr. Dennis D. Kim M.B.A. (Age 52)
M.D., MBA, Chief Medical Officer
Comp: $406.11k

Mr. Lewis J. Stuart B.A. (Age 63)
BA, M.B.A., MBA, Chief Commercial Officer
Comp: $378.79k

Mr. Daniel Menold (Age 52)
VP of Fin.

Dr. Charles A. McWherter Ph.D. (Age 67)
Sr. VP & Chief Scientific Officer

Mr. Paul T. Quinlan (Age 59)
Gen. Counsel, Chief Compliance Officer & Corp. Sec.

Mr. Ken Boehm
Sr. VP of HR

Mr. Patrick J. O'Mara (Age 61)
Sr. VP of Bus. Devel.

Dr. Robert L. Martin (Age 60)
Sr. VP of Manufacturing & Nonclinical Devel.

Ms. Klara A. Dickinson-Eason (Age 54)
Chief Regulatory & Quality Assurance Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CBAY Stock - Frequently Asked Questions

Should I buy or sell CymaBay Therapeutics stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CymaBay Therapeutics in the last twelve months. There are currently 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CBAY shares.
View CBAY analyst ratings or view top-rated stocks.
What is CymaBay Therapeutics' stock price forecast for 2022?: 3 equities research analysts have issued 12 month price objectives for CymaBay Therapeutics' shares. Their CBAY share price forecasts range from $8.00 to $14.00. On average, they anticipate the company's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 214.3% from the stock's current price.
View analysts price targets for CBAY or view top-rated stocks among Wall Street analysts.
How have CBAY shares performed in 2022?: CymaBay Therapeutics' stock was trading at $3.38 at the beginning of the year. Since then, CBAY shares have increased by 3.6% and is now trading at $3.50.
View the best growth stocks for 2022 here.
When is CymaBay Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our CBAY earnings forecast.

How were CymaBay Therapeutics' earnings last quarter?: CymaBay Therapeutics, Inc. (NASDAQ:CBAY) released its quarterly earnings data on Thursday, August, 11th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by $0.01. During the same quarter in the prior year, the business earned ($0.34) earnings per share.
What other stocks do shareholders of CymaBay Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other CymaBay Therapeutics investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Advanced Micro Devices (AMD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA), Novavax (NVAX), Corbus Pharmaceuticals (CRBP), Energy Transfer (ET) and Viking Therapeutics (VKTX).
What is CymaBay Therapeutics' stock symbol?: CymaBay Therapeutics trades on the NASDAQ under the ticker symbol "CBAY."
How do I buy shares of CymaBay Therapeutics?: Shares of CBAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is CymaBay Therapeutics' stock price today?: One share of CBAY stock can currently be purchased for approximately $3.50.
How much money does CymaBay Therapeutics make?: CymaBay Therapeutics (NASDAQ:CBAY) has a market capitalization of $296.37 million. The biopharmaceutical company earns $-90,000,000.00 in net income (profit) each year or ($1.30) on an earnings per share basis.
How can I contact CymaBay Therapeutics?: CymaBay Therapeutics' mailing address is 7575 GATEWAY BOULEVARD SUITE 110, NEWARK CA, 94560. The official website for the company is www.cymabay.com. The biopharmaceutical company can be reached via phone at (510) 293-8800, via email at investors@cymabay.com, or via fax at 510-293-9090.

This page (NASDAQ:CBAY) was last updated on 9/30/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

CymaBay Therapeutics - CBAY Stock Forecast, Price & News

CymaBay Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows